Table 3.
Median values of albumin/creatinine ratio and estimated GFR at each year of follow-up in patients randomized to insulin-sensitizing drugs versus insulin-providing drugs
| Time of Follow-Up | Albumin/creatinine ratio (mg/g) | Estimated GFR (ml/min per 1.73 m2) | ||||||
|---|---|---|---|---|---|---|---|---|
| IS | IP | IS | IP | |||||
| N | Median (IQR) | N | Median (IQR) | N | Mean (SD) | N | Mean (SD) | |
| Baseline | 922 | 11.5 (5.0–46.7) | 877 | 12.1 (5.3–41.3) | 922 | 75.0 (20.6) | 877 | 76.1 (19.5) |
| Year 1 | 800 | 13.2 (6.1–45.5) | 569 | 11.6 (5.4–40.5) | 800 | 70.6 (20.6) | 569 | 74.4 (20.2) |
| Year 2 | 820 | 14.7 (6.2–59.4) | 733 | 12.2 (5.2–46.0) | 820 | 70.8 (21.5) | 733 | 70.2 (21.6) |
| Year 3 | 813 | 14.8 (6.2–52.9) | 771 | 12.9 (5.5–46.3) | 813 | 68.3 (21.9) | 771 | 67.7 (20.9) |
| Year 4 | 687 | 16.4 (6.0–63.5) | 672 | 11.6 (5.3–50.3) | 687 | 66.9 (21.6) | 672 | 66.8 (21.4) |
| Year 5 | 416 | 15.7 (6.2–55.4) | 417 | 12.4 (5.8–50.6) | 416 | 66.3 (22.6) | 417 | 66.8 (21.1) |
| P value for trend | <0.001 | 0.21 | <0.001 | <0.001 | ||||
IS, insulin-sensitizing drugs; IP, insulin-providing drugs; IQR, interquartile range.